Natco Pharma Q2 FY27 net profit falls 61% to ₹203 crore as revenue slips
Synopsis
Natco Pharma's Q2 FY27 earnings tell a stark story of post-exclusivity correction: net profit collapsed 60.8% year-on-year to ₹203 crore and revenue fell 29% to ₹967 crore, reflecting the company's heavy dependence on US limited-competition generics. The board has still declared a second interim dividend of ₹1.25 per share, with the record date set for 19 November 2026.
Key Takeaways
Natco Pharma reported Q2 FY27 net profit of ₹203 crore , down 60.8 per cent YoY from ₹518 crore .
Revenue from operations fell 29 per cent to ₹967 crore , from ₹1,363 crore in Q2 FY26 .
EBITDA declined 55.4 per cent to ₹258.3 crore ; margin compressed by 1,580 bps to 26.7 per cent .
Other income fell to ₹52 crore from ₹100 crore a year earlier.
Shares fell up to 3.60 per cent intra-day, closing 1.70 per cent lower at ₹795.05 .
Board declared a second interim dividend of ₹1.25 per share ; record date 19 November 2026 , payment from 27 November 2026 .
Natco Pharma Limited on Friday, 13 November 2026 reported a steep fall in its earnings for the July–September quarter of FY27 (Q2 FY27), with net profit plunging 60.8 per cent year-on-year to ₹203 crore, down from ₹518 crore in Q2 FY26. Revenue from operations also contracted sharply, sliding 29 per cent to ₹967 crore from ₹1,363 crore in the year-ago period, according to the company's stock exchange filing.
Profitability Under Pressure
At the operating level, Natco Pharma's earnings before interest, taxes, depreciation and amortisation (EBITDA) dropped 55.4 per cent to ₹258.3 crore, compared to ₹579 crore in Q2 FY26. The EBITDA margin narrowed sharply to 26.7 per cent, a compression of 1,580 basis points from the 42.5 per cent margin recorded in the same quarter of the previous year.
Other income also declined, coming in at ₹52 crore against ₹100 crore in the corresponding period, adding further weight to an already challenging quarter, according to the regulatory filing.
Stock Reaction
Investors responded swiftly to the results. Natco Pharma shares fell as much as 3.60 per cent intra-day, touching a low of ₹779.65. The stock recovered partially but continued to trade in negative territory, closing the last leg of the session down 1.70 per cent at ₹795.05.
Interim Dividend Declared
Despite the quarterly setback, the Board of Directors declared a second interim dividend of ₹1.25 per equity share (62.50 per cent on the face value of ₹2 per share) for FY2026-27. The record date for determining eligible shareholders has been fixed as Thursday, 19 November 2026, with dividend payments set to commence from 27 November 2026.
Context and What to Watch
The sharp year-on-year decline follows an exceptionally strong Q2 FY26, partly driven by high-value exclusivity-driven product launches in the US generics market — a segment known for outsized quarterly swings. Notably, Natco's business model is heavily reliant on first-to-file and limited-competition generic opportunities in the United States, which can produce significant revenue peaks and troughs as exclusivity windows open and close. Analysts and investors will be watching closely for management commentary on the pipeline of upcoming para IV filings and any new exclusivity launches that could restore earnings momentum in the second half of FY27.
Point of View
Leaving a gaping base-effect crater. The 1,580-basis-point EBITDA margin compression is not just a quarterly blip — it signals how thin the underlying business can look once blockbuster generic tailwinds fade. The board's decision to maintain an interim dividend offers a floor of confidence, but investors will need clarity on the next wave of limited-competition launches before re-rating the stock. Without a credible near-term pipeline catalyst, the share price is likely to remain range-bound.
NationPress
14 Nov 2026
Frequently Asked Questions
What were Natco Pharma's Q2 FY27 results?
Natco Pharma reported a net profit of ₹203 crore for Q2 FY27, a 60.8 per cent drop year-on-year from ₹518 crore. Revenue from operations also fell 29 per cent to ₹967 crore, while EBITDA declined 55.4 per cent to ₹258.3 crore.
Why did Natco Pharma's profits fall so sharply?
The decline is largely attributed to the absence of high-value, limited-competition generic product revenues that boosted the year-ago quarter, particularly in the US market. Natco's earnings are sensitive to exclusivity-driven launches, which can cause significant swings between quarters.
How did Natco Pharma's share price react to the Q2 results?
Natco Pharma shares fell as much as 3.60 per cent intra-day to a low of ₹779.65 following the results. The stock recovered partially, closing the session 1.70 per cent lower at ₹795.05.
Has Natco Pharma declared any dividend for Q2 FY27?
Yes. The Board of Directors declared a second interim dividend of ₹1.25 per equity share (62.50 per cent on face value of ₹2) for FY2026-27. The record date is 19 November 2026, with payment commencing from 27 November 2026.
What is Natco Pharma's EBITDA margin for Q2 FY27?
Natco Pharma's EBITDA margin for Q2 FY27 stood at 26.7 per cent, a sharp contraction of 1,580 basis points compared to 42.5 per cent in Q2 FY26, reflecting the significant drop in high-margin generics revenue.
